Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry.

Marques R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, Beaure d'Augères G, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC, Jansen AC.

Front Neurol. 2019 Oct 25;10:1144. doi: 10.3389/fneur.2019.01144. eCollection 2019.

2.

Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study.

Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, D'Amato L, Beaure d'Augères G, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC.

Front Neurol. 2019 Aug 2;10:821. doi: 10.3389/fneur.2019.00821. eCollection 2019.

3.

Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex.

Jansen AC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Kingswood JC.

Front Neurol. 2019 Jul 3;10:705. doi: 10.3389/fneur.2019.00705. eCollection 2019.

4.

A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report.

Auvin S, Bissler JJ, Cottin V, Fujimoto A, Hofbauer GFL, Jansen AC, Jóźwiak S, Kerecuk L, Kingswood JC, Moavero R, Torra R, Villanueva V.

Orphanet J Rare Dis. 2019 Apr 30;14(1):91. doi: 10.1186/s13023-019-1072-y.

5.

Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study.

Nabbout R, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen A, Kingswood JC; TOSCA Consortium and TOSCA Investigators.

Epilepsia Open. 2018 Dec 21;4(1):73-84. doi: 10.1002/epi4.12286. eCollection 2019 Mar.

6.

Cannabis based drugs: finding the balance between benefit and harm.

Kingswood JC.

BMJ. 2018 Dec 27;363:k5213. doi: 10.1136/bmj.k5213. No abstract available.

PMID:
30591432
7.

The UK guidelines for management and surveillance of Tuberous Sclerosis Complex.

Amin S, Kingswood JC, Bolton PF, Elmslie F, Gale DP, Harland C, Johnson SR, Parker A, Sampson JR, Smeaton M, Wright I, O'Callaghan FJ.

QJM. 2019 Mar 1;112(3):171-182. doi: 10.1093/qjmed/hcy215.

PMID:
30247655
8.

TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study.

de Vries PJ, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D'Amato L, d'Augères GB, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Kingswood JC, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA Consortium and TOSCA Investigators.

Orphanet J Rare Dis. 2018 Sep 10;13(1):157. doi: 10.1186/s13023-018-0901-8.

9.

Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness.

Kingswood JC, Belousova E, Benedik MP, Carter T, Cottin V, Curatolo P, Dahlin M, D' Amato L, d'Augères GB, de Vries PJ, Ferreira JC, Feucht M, Fladrowski C, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Marques R, Nabbout R, O'Callaghan F, Qin J, Sander V, Sauter M, Shah S, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC.

Nephrol Dial Transplant. 2019 Mar 1;34(3):502-508. doi: 10.1093/ndt/gfy063.

10.

Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies.

Franz DN, Budde K, Kingswood JC, Belousova E, Sparagana S, de Vries PJ, Berkowitz N, Ridolfi A, Bissler JJ.

J Eur Acad Dermatol Venereol. 2018 Oct;32(10):1796-1803. doi: 10.1111/jdv.14964. Epub 2018 Jul 16.

PMID:
29569806
11.

Pooled analysis of menstrual irregularities from three major clinical studies evaluating everolimus for the treatment of tuberous sclerosis complex.

Sparagana S, Franz DN, Krueger DA, Bissler JJ, Berkowitz N, Burock K, Kingswood JC.

PLoS One. 2017 Oct 12;12(10):e0186235. doi: 10.1371/journal.pone.0186235. eCollection 2017.

12.

The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.

Bissler JJ, Franz DN, Frost MD, Belousova E, Bebin EM, Sparagana S, Berkowitz N, Ridolfi A, Kingswood JC.

Pediatr Nephrol. 2018 Jan;33(1):101-109. doi: 10.1007/s00467-017-3806-1. Epub 2017 Oct 9.

13.

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study.

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Belousova E, Frost MD, Sauter M, Brakemeier S, de Vries PJ, Berkowitz N, Voi M, Peyrard S, Budde K.

PLoS One. 2017 Aug 9;12(8):e0180939. doi: 10.1371/journal.pone.0180939. eCollection 2017.

14.

Management of everolimus-associated adverse events in patients with tuberous sclerosis complex: a practical guide.

Davies M, Saxena A, Kingswood JC.

Orphanet J Rare Dis. 2017 Feb 15;12(1):35. doi: 10.1186/s13023-017-0581-9. Review.

15.

TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.

Kingswood JC, d'Augères GB, Belousova E, Ferreira JC, Carter T, Castellana R, Cottin V, Curatolo P, Dahlin M, de Vries PJ, Feucht M, Fladrowski C, Gislimberti G, Hertzberg C, Jozwiak S, Lawson JA, Macaya A, Nabbout R, O'Callaghan F, Benedik MP, Qin J, Marques R, Sander V, Sauter M, Takahashi Y, Touraine R, Youroukos S, Zonnenberg B, Jansen AC; TOSCA consortium and TOSCA investigators.

Orphanet J Rare Dis. 2017 Jan 5;12(1):2. doi: 10.1186/s13023-016-0553-5.

16.

Optimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic review.

Bissler JJ, Kingswood JC.

Ther Adv Urol. 2016 Aug;8(4):279-290. Epub 2016 Apr 6. Review.

17.

The economic burden of tuberous sclerosis complex in the UK: A retrospective cohort study in the Clinical Practice Research Datalink.

Kingswood JC, Crawford P, Johnson SR, Sampson JR, Shepherd C, Demuth D, Erhard C, Nasuti P, Patel K, Myland M, Pinnegar A, Magestro M, Gray E.

J Med Econ. 2016 Nov;19(11):1087-1098. Epub 2016 Jun 22.

PMID:
27267148
18.

Review of the Tuberous Sclerosis Renal Guidelines from the 2012 Consensus Conference: Current Data and Future Study.

Kingswood JC, Bissler JJ, Budde K, Hulbert J, Guay-Woodford L, Sampson JR, Sauter M, Cox J, Patel U, Elmslie F, Anderson C, Zonnenberg BA.

Nephron. 2016;134(2):51-58. Epub 2016 Aug 10. Review.

19.

The economic burden of tuberous sclerosis complex in UK patients with renal manifestations: a retrospective cohort study in the clinical practice research datalink (CPRD).

Kingswood JC, Nasuti P, Patel K, Myland M, Siva V, Gray E.

J Med Econ. 2016 Dec;19(12):1116-1126. Epub 2016 Jun 25.

PMID:
27310569
20.

Tuberous sclerosis complex.

Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA.

Nat Rev Dis Primers. 2016 May 26;2:16035. doi: 10.1038/nrdp.2016.35. Review.

PMID:
27226234
21.

The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions.

Curatolo P, Bjørnvold M, Dill PE, Ferreira JC, Feucht M, Hertzberg C, Jansen A, Jóźwiak S, Kingswood JC, Kotulska K, Macaya A, Moavero R, Nabbout R, Zonnenberg BA.

Drugs. 2016 Apr;76(5):551-65. doi: 10.1007/s40265-016-0552-9. Review.

PMID:
26927950
22.

Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.

Budde K, Zonnenberg BA, Frost M, Cheung W, Urva S, Brechenmacher T, Stein K, Chen D, Kingswood JC, Bissler JJ.

Br J Clin Pharmacol. 2016 May;81(5):958-70. doi: 10.1111/bcp.12834. Epub 2016 Mar 5.

23.

Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial.

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Berkowitz N, Miao S, Segal S, Peyrard S, Budde K.

Nephrol Dial Transplant. 2016 Jan;31(1):111-9. doi: 10.1093/ndt/gfv249. Epub 2015 Jul 8.

PMID:
26156073
24.

TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex.

Kingswood JC, Bruzzi P, Curatolo P, de Vries PJ, Fladrowski C, Hertzberg C, Jansen AC, Jozwiak S, Nabbout R, Sauter M, Touraine R, O'Callaghan F, Zonnenberg B, Crippa S, Comis S, d'Augères GB, Belousova E, Carter T, Cottin V, Dahlin M, Ferreira JC, Macaya A, Benedik MP, Sander V, Youroukos S, Castellana R, Ulker B, Feucht M.

Orphanet J Rare Dis. 2014 Nov 26;9:182. doi: 10.1186/s13023-014-0182-9.

25.

The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, Phase 3 trial EXIST-1.

Kingswood JC, Jozwiak S, Belousova ED, Frost MD, Kuperman RA, Bebin EM, Korf BR, Flamini JR, Kohrman MH, Sparagana SP, Wu JY, Brechenmacher T, Stein K, Berkowitz N, Bissler JJ, Franz DN.

Nephrol Dial Transplant. 2014 Jun;29(6):1203-10. doi: 10.1093/ndt/gfu013. Epub 2014 Apr 11.

26.

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.

Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, Whittemore VH, Chen D, Sahmoud T, Shah G, Lincy J, Lebwohl D, Budde K.

Lancet. 2013 Mar 9;381(9869):817-24.

PMID:
23312829
27.

Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial.

Davies DM, de Vries PJ, Johnson SR, McCartney DL, Cox JA, Serra AL, Watson PC, Howe CJ, Doyle T, Pointon K, Cross JJ, Tattersfield AE, Kingswood JC, Sampson JR.

Clin Cancer Res. 2011 Jun 15;17(12):4071-81. doi: 10.1158/1078-0432.CCR-11-0445. Epub 2011 Apr 27.

28.

Sirolimus therapy in tuberous sclerosis or sporadic lymphangioleiomyomatosis.

Davies DM, Johnson SR, Tattersfield AE, Kingswood JC, Cox JA, McCartney DL, Doyle T, Elmslie F, Saggar A, de Vries PJ, Sampson JR.

N Engl J Med. 2008 Jan 10;358(2):200-3. doi: 10.1056/NEJMc072500. No abstract available.

PMID:
18184971
29.

Tuberose sclerosis complex: analysis of growth rates aids differentiation of renal cell carcinoma from atypical or minimal-fat-containing angiomyolipoma.

Patel U, Simpson E, Kingswood JC, Saggar-Malik AK.

Clin Radiol. 2005 Jun;60(6):665-73; discussion 663-4.

PMID:
16038693
30.

Renal angiomyolipomata.

Bissler JJ, Kingswood JC.

Kidney Int. 2004 Sep;66(3):924-34. Review.

31.

Possible cross-infection with hepatitis C virus of an unusual genotype on a haemodialysis unit.

McElborough D, Paul J, Hargreaves R, Kingswood JC, Harris K, Teo CG.

J Hosp Infect. 2001 Apr;47(4):335-6. No abstract available.

PMID:
11289782
32.

How reproducible is diurnal blood pressure rhythm in patients with secondary (renal) hypertension?

Covic A, Goldsmith DJ, Farmer CK, Cox J, Dallyn P, Sharpstone P, Kingswood JC.

Rev Med Chir Soc Med Nat Iasi. 1999 Jan-Jun;103(1-2):88-93.

PMID:
10756891
33.

Progression of diabetic nephropathy--is diurnal blood pressure rhythm as important as absolute blood pressure level?

Farmer CK, Goldsmith DJ, Quin JD, Dallyn P, Cox J, Kingswood JC, Sharpstone P.

Nephrol Dial Transplant. 1998 Mar;13(3):635-9.

PMID:
9550639
34.

Maintenance of adequate dialysis in a patient with peritoneal calcification using tidal peritoneal dialysis.

Farmer CK, Goldsmith DJ, Sharpstone P, Kingswood JC.

Clin Nephrol. 1998 Jan;49(1):55-8.

PMID:
9491288
35.

An investigation of the effect of advancing uraemia, renal replacement therapy and renal transplantation on blood pressure diurnal variability.

Farmer CK, Goldsmith DJ, Cox J, Dallyn P, Kingswood JC, Sharpstone P.

Nephrol Dial Transplant. 1997 Nov;12(11):2301-7.

PMID:
9394315
36.

Endoluminal brushing of blocked permanent indwelling haemodialysis catheters saves money.

Farmer CK, Greenwood E, Goldsmith DJ, Kingswood JC, Sharpstone P.

Nephrol Dial Transplant. 1997 Sep;12(9):2040. No abstract available.

PMID:
9306383
37.

Reversible acute renal failure induced by losartan in a renal transplant recipient.

Ostermann M, Goldsmith DJ, Doyle T, Kingswood JC, Sharpstone P.

Postgrad Med J. 1997 Feb;73(856):105-7.

38.

Quinine clearance in continuous venovenous hemofiltration.

Davies JG, Greenwood EF, Kingswood JC, Sharpstone P, Street MK.

Ann Pharmacother. 1996 May;30(5):487-90.

PMID:
8740330
39.

Haemodynamic changes measured by transthoracic bioimpedance during treatment with recombinant human erythropoietin.

Jones MA, Kingswood JC, Dallyn PE, Sharpstone P.

Clin Exp Hypertens. 1996 Jan;18(1):51-64.

PMID:
8822233
40.

A four-year audit of interventional treatment for atheromatous renal artery stenosis.

Donohoe P, de Takats D, Bishop N, Burwood RJ, Doyle T, Goldsmith D, Hamilton G, Kenney I, Kingswood JC, Sharpstone P.

Contrib Nephrol. 1996;119:78-82. No abstract available.

PMID:
8783595
41.

Drug removal in continuous haemofiltration and haemodialysis.

Davies JG, Kingswood JC, Sharpstone P, Street MK.

Br J Hosp Med. 1995 Nov 15-Dec 12;54(10):524-8. Review.

PMID:
8574497
42.

Changes in diurnal blood pressure variation and red cell and plasma volumes in patients with renal failure who develop erythropoietin-induced hypertension.

Jones MA, Kingswood JC, Dallyn PE, Andrew M, Cheetham A, Burwood R, Sharpstone P.

Clin Nephrol. 1995 Sep;44(3):193-200.

PMID:
8556836
43.

Reduced nocturnal blood pressure fall is similar in continuous ambulatory peritoneal dialysis to that in hemodialysis and undialysed end-stage renal disease.

Jones MA, Sharpstone P, Dallyn PE, Kingswood JC.

Clin Nephrol. 1994 Oct;42(4):273-5. No abstract available.

PMID:
7834923
44.

Resolution of cyclosporin-induced gingival hypertrophy with metronidazole.

Wong W, Hodge MG, Lewis A, Sharpstone P, Kingswood JC.

Lancet. 1994 Apr 16;343(8903):986. No abstract available.

PMID:
7909047
45.

Does dialysis-associated amyloidosis resolve after transplantation?

Nelson SR, Sharpstone P, Kingswood JC.

Nephrol Dial Transplant. 1993;8(4):369-70. No abstract available.

PMID:
7685506
46.
47.

Encephalopathy in patient taking aluminium-containing agents, including sucralfate.

Withers DJ, Woolf AS, Kingswood JC, Tsang WN, Mansell MA.

Lancet. 1989 Sep 16;2(8664):674. No abstract available.

PMID:
2570918
48.

Effect of nadolol on plasma lipids in hyperthyroidism.

Littley MD, Kingswood JC, John R, Lazarus JH.

Horm Metab Res. 1989 Jun;21(6):331-3.

PMID:
2777191
49.

The effect of nadolol on heart rate in hyperthyroidism. A controlled trial.

Lazarus JH, Kingswood JC, John R.

Acta Endocrinol (Copenh). 1987 Jan;114(1):102-6.

PMID:
3544631
50.

Sodium, blood pressure, and calcium antagonists.

Kingswood JC, Thompson FD.

Lancet. 1986 May 10;1(8489):1102. No abstract available.

PMID:
2871372

Supplemental Content

Loading ...
Support Center